Co-morbid beta-amyloid toxicity and stroke produce impairments in an ambiguous context task in rats without any impairment in spatial working memory

Neurobiology of Learning and Memory

Volumn 119, Issue , 2015, Pages 42-51

  Keeley, R J ^a   Hong, N S ^a   Fisher, A ^a   McDonald, R J ^a  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Acetylcholine; Alzheimer's disease (AD); Beta amyloid; Cue ambiguity; Discriminative fear conditioning to context; Hippocampus; Morris water task; Stroke

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; CHOLINE ACETYLTRANSFERASE; ENDOTHELIN 1;

ADULT; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DISCRIMINATION LEARNING; DISEASE ASSOCIATION; DISEASE COURSE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MENTAL TASK; MORRIS WATER MAZE TEST; NEUROTOXICITY; NONHUMAN; RAT; SPATIAL MEMORY; TASK PERFORMANCE; TREND STUDY; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; CONDITIONING; DISEASE MODEL; DRUG EFFECTS; FEAR; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEARNING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPTUM NUCLEUS; SHORT TERM MEMORY; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOLINE O-ACETYLTRANSFERASE; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FEAR; INFUSIONS, INTRAVENTRICULAR; LEARNING; MALE; MEMORY, SHORT-TERM; RATS; RATS, WISTAR; SEPTAL NUCLEI; SPATIAL MEMORY; STROKE;

EID: 84922389810     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2015.01.001     Document Type: Article

References (84)

1. Amtul Z., Nikolova S., Gao L., Keeley R.J., Bechberger J.F., Fisher A.L., et al. Comorbid Abeta toxicity and stroke: Hippocampal atrophy, pathology, and cognitive deficit. Neurobiology Aging 2014, 10.1016/j.neurobiolaging.2014.01.005.
2. Amtul Z., Whitehead S., Keeley R., Bechberger J., Fisher A., McDonald R., et al. Co-morbid rat model of ischemia and beta-amyloid toxicity: Striatal and cortical degeneration. Brain Pathology 2014, 10.1111/bpa.12149.
3. Antoniadis E.A., McDonald R.J. Discriminative fear conditioning to context expressed by multiple measures of fear in the rat. Behavioural Brain Research 1999, 101(1):1-13. 10.1016/s0166-4328(98)00056-4.
4. Antoniadis E.A., McDonald R.J. Amygdala, hippocampus and discriminative fear conditioning to context. Behavioural Brain Research 2000, 109(1):141-142. 10.1016/s0166-4328(00)00152-2.
5. Antoniadis E.A., McDonald R.J. Fornix, medial prefrontal cortex, nucleus accumbens, and mediodorsal thalamic nucleus: Roles in a fear-based context discrimination task. Neurobiology of Learning and Memory 2006, 85(1):71-85. 10.1016/j.nlm.2005.08.011.
6. Arnold S.E., Hyman B.T., Van Hoesen G.W. Neuropathologic changes of the temporal pole in Alzheimer's disease and Pick's disease. Archives Neurology 1994, 51(2):145-150.
7. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: Relations to beta-amyloid peptides, cognition, and treatment strategies. Progress in Neurobiology 2002, 68(3):209-245. 10.1016/S0301-0082(02)00079-5.
8. Bowen D.M., Benton J.S., Spillane J.A., Smith C.C., Allen S.J. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. Journal of the Neurological Sciences 1982, 57(2-3):191-202.
9. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991, 82(4):239-259.
10. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology Aging 1997, 18(4):351-357.
11. Cechetto D.F., Hachinski V., Whitehead S.N. Vascular risk factors and Alzheimer's disease. Expert Review Neurotherapeutics 2008, 8(5):743-750. 10.1586/14737175.8.5.743.
12. Cheng G., Whitehead S.N., Hachinski V., Cechetto D.F. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiology of Disease 2006, 23(1):140-151. 10.1016/j.nbd.2006.02.008.
13. Cleary J., Hittner J.M., Semotuk M., Mantyh P., O'Hare E. Beta-amyloid (1-40) effects on behavior and memory. Brain Research 1995, 682(1-2):69-74.
14. Craig L.A., Hong N.S., Kopp J., McDonald R.J. Emergence of spatial impairment in rats following specific cholinergic depletion of the medial septum combined with chronic stress. European Journal of Neuroscience 2008, 27(9):2262-2271. 10.1111/j.1460-9568.2008.06179.x.
15. Craig L.A., Hong N.S., Kopp J., McDonald R.J. Reduced cholinergic status in hippocampus produces spatial memory deficits when combined with kainic acid induced seizures. Hippocampus 2008, 18(11):1112-1121. 10.1002/hipo.20471.
16. Craig L.A., Hong N.S., Kopp J., McDonald R.J. Cholinergic depletion of the medial septum followed by phase shifting does not impair memory or rest-activity rhythms measured under standard light/dark conditions in rats. Brain Research Bulletin 2009, 79(1):53-62. 10.1016/j.brainresbull.2008.10.013.
17. Craig L.A., Hong N.S., Kopp J., McDonald R.J. Selective lesion of medial septal cholinergic neurons followed by a mini-stroke impairs spatial learning in rats. Experimental Brain Research 2009, 193(1):29-42. 10.1007/s00221-008-1592-5.
18. Craig L.A., Hong N.S., McDonald R.J. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neuroscience & Biobehavioral Reviews 2011, 35(6):1397-1409. 10.1016/j.neubiorev.2011.03.001.
19. Davies S., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2(8000):1403.
20. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281(15):1401-1406.
21. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology 2002, 51(2):145-155.
22. Delobette S., Privat A., Maurice T. In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. European Journal of Pharmacology 1997, 319(1):1-4.
23. Doraiswamy P.M., Leon J., Cummings J.L., Marin D., Neumann P.J. Prevalence and impact of medical comorbidity in Alzheimer's disease. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2002, 57(3):M173-M177.
24. Efange S.M., Garland E.M., Staley J.K., Khare A.B., Mash D.C. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiology of Aging 1997, 18(4):407-413.
25. Ergul A., Elgebaly M.M., Middlemore M.L., Li W., Elewa H., Switzer J.A., et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurology 2007, 7:33. 10.1186/1471-2377-7-33.
26. Ferbinteanu J., Ray C., McDonald R.J. Both dorsal and ventral hippocampus contribute to spatial learning in Long-Evans rats. Neuroscience Letters 2003, 345(2):131-135. 10.1016/s0304-3940(03)00473-7.
27. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., et al. Role of genes and environments for explaining Alzheimer disease. Archives of General Psychiatry 2006, 63(2):168-174. 10.1001/archpsyc.63.2.168.
28. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications 1984, 122(3):1131-1135.
29. Hachinski V. Relevance of cerebrovascular changes to mental function. Mechanisms of Ageing and Development 1979, 9(1-2):173-183.
30. Hachinski V. Stroke and Alzheimer disease fellow travelers or partners in crime?. Archives of Neurology 2011, 68(6):797-798.
31. Hankey G.J. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovascular Diseases 2003, 16(Suppl 1):14-19. 10.1159/000069936.
32. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356. 10.1126/science.1072994.
33. Joshi A., Ringman J.M., Lee A.S., Juarez K.O., Mendez M.F. Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. Journal of Neurology 2012, 259(10):2182-2188.
34. Kaneko I., Morimoto K., Kubo T. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: Conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 2001, 104(4):1003-1011.
35. Kar S., Quirion R. Amyloid beta peptides and central cholinergic neurons: Functional interrelationship and relevance to Alzheimer's disease pathology. Progress in Brain Research 2004, 145:261-274. 10.1016/s0079-6123(03)45018-8.
36. Kolb B. Prefrontal lesions alter eating and hoarding behavior in rats. Physiology & Behavior 1974, 12(3):507-511. 10.1016/0031-9384(74)90130-9.
37. Kubo T., Nishimura S., Kumagae Y., Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. Journal of Neuroscience Research 2002, 70(3):474-483. 10.1002/jnr.10391.
38. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Annals of Neurology 1996, 40(3):399-410. 10.1002/ana.410400309.
39. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440(7082):352-357. 10.1038/nature04533.
40. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences United States 1985, 82(12):4245-4249.
41. McDonald R.J. Multiple combinations of co-factors produce variants of age-related cognitive decline: A theory. Canadian Journal of Experimental Psychology 2002, 56(3):221-239.
42. McDonald R.J., Craig L.A., Hong N.S. The etiology of age-related dementia is more complicated than we think. Behavioural Brain Research 2010, 214(1):3-11. 10.1016/j.bbr.2010.05.005.
43. McDonald R.J., Foong N., Ray C., Rizos Z., Hong N.S. The role of medial prefrontal cortex in context-specific inhibition during reversal learning of a visual discrimination. Experimental Brain Research 2007, 177(4):509-519. 10.1007/s00221-006-0699-9.
44. McDonald R.J., Hong N.S. How does a specific learning and memory system in the mammalian brain gain control of behavior?. Hippocampus 2013, 23(11):1084-1102. 10.1002/hipo.22177.
45. McDonald R.J., King A.L., Foong N., Rizos Z., Hong N.S. Neurotoxic lesions of the medial prefrontal cortex or medial striatum impair multiple-location place learning in the water task: Evidence for neural structures with complementary roles in behavioural flexibility. Experimental Brain Research 2008, 187(3):419-427. 10.1007/s00221-008-1314-z.
46. McDonald R.J., Murphy R.A., Guarraci F.A., Gortler J.R., White N.M., Baker A.G. Systematic comparison of the effects of hippocampal and fornix-fimbria lesions on acquisition of three configural discriminations. Hippocampus 1997, 7(4):371-388. 10.1002/(SICI)1098-1063(1997) 7:4<371::AID-HIPO3>3.0.CO;2-M.
47. McDonald R.J., White N.M. Hippocampal and nonhippocampal contributions to place learning in rats. Behavioral Neuroscience 1995, 109(4):579-593.
48. Mesulam M., Shaw P., Mash D., Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Annals of Neurology 2004, 55(6):815-828. 10.1002/ana.20100.
49. Minati L., Edginton T., Bruzzone M.G., Giaccone G. Current concepts in Alzheimer's disease: A multidisciplinary review. American Journal of Alzheimers Disease and Other Dementias 2009, 24(2):95-121. 10.1177/1533317508328602.
50. Moser M.B., Moser E.I., Forrest E., Andersen P., Morris R.G. Spatial learning with a minislab in the dorsal hippocampus. Proceedings of the National Academy of Sciences 1995, 92(21):9697-9701.
51. Mufson E.J., Counts S.E., Fahnestock M., Ginsberg S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Current Alzheimer Research 2007, 4(4):340-350.
52. Nabeshima T., Nitta A. Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats. Tohoku Journal of Experimental Medicine 1994, 174(3):241-249.
53. Papadopulos F., Spinelli M., Valente S., Foroni L., Orrico C., Alviano F., et al. Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastructural Pathology 2007, 31(6):401-407. 10.1080/01913120701719189.
54. Pedersen W.A., Kloczewiak M.A., Blusztajn J.K. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proceedings of the National Academy of Sciences United States 1996, 93(15):8068-8071.
55. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test-scores in senile dementia. British Medical Journal 1978, 2(6150):1457-1459.
56. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991, 7(5):695-702.
57. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Research 1991, 563(1-2):311-314.
58. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proceedings of the National Academy of Sciences United States 1995, 92(26):12260-12264.
59. Quirk G.J., Russo G.K., Barron J.L., Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. Journal of Neuroscience 2000, 20(16):6225-6231.
60. Sassin I., Schultz C., Thal D.R., Rüb U., Arai K., Braak E., et al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathologica 2000, 100(3):259-269.
61. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69(24):2197-2204. 10.1212/01.wnl.0000271090.28148.24.
62. Shi J., Yang S.H., Stubley L., Day A.L., Simpkins J.W. Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Research 2000, 853(1):1-4.
63. Small D.L., Morley P., Buchan A.M. Biology of ischemic cerebral cell death. Progress in Cardiovascular Diseases 1999, 42(3):185-207.
64. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277(10):813-817.
65. Snyder J.S., Hong N.S., McDonald R.J., Wojtowicz J.M. A role for adult neurogenesis in spatial long-term memory. Neuroscience 2005, 130(4):843-852. 10.1016/j.neuroscience.2004.10.009.
66. Song I.-U., Kim J.-S., Kim Y.-I., Eah K.-Y., Lee K.-S. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology 2007, 20(2):93-98. 10.1097/WNN.0b013e31805d859e.
67. Sosa-Ortiz A.L., Acosta-Castillo I., Prince M.J. Epidemiology of dementias and Alzheimer's disease. Archives of Medical Research 2012, 43(8):600-608. 10.1016/j.arcmed.2012.11.003.
68. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetic Medicine 1999, 16(2):93-112.
69. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences United Sciences 1993, 90(5):1977-1981.
70. Sutherland R., McDonald R., Savage D. Prenatal exposure to moderate levels of ethanol can have long-lasting effects on learning and memory in adult offspring. Psychobiology 2000, 28(4):532-539. 10.3758/BF03332012.
71. Thies W., Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9(2):208-245. 10.1016/j.jalz.2013.02.003.
72. Tolppanen A.M., Lavikainen P., Solomon A., Kivipelto M., Soininen H., Hartikainen S. Incidence of stroke in people with Alzheimer disease: A national register-based approach. Neurology 2013, 80(4):353-358. 10.1212/WNL.0b013e31827f08c5.
73. Tran M.H., Yamada K., Nabeshima T. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: A minireview. Peptides 2002, 23(7):1271-1283.
74. Uylings H., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex?. Behavioural Brain Research 2003, 146(1):3-17.
75. Van Broeckhoven C., Backhovens H., Cruts M., De Winter G., Bruyland M., Cras P., et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nature Genetics 1992, 2(4):335-339. 10.1038/ng1292-335.
76. Vermeer S.E., Longstreth W.T., Koudstaal P.J. Silent brain infarcts: A systematic review. The Lancet. Neurology 2007, 6(7):611-619. 10.1016/S1474-4422(07)70170-9.
77. Whitehead S.N., Cheng G.L., Hachinski V., Cechetto D.F. Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity - II. Effects of triflusal. Stroke 2005, 36(8):1782-1789. 10.1161/01.STR.0000173405.02425.d6.
78. Whitehead S.N., Cheng G., Hachinski V.C., Cechetto D.F. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke 2007, 38(12):3245-3250. 10.1161/strokeaha.107.492660.
79. Whitehead S.N., Hachinski V.C., Cechetto D.F. Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity - Inflammatory responses. Stroke 2005, 36(1):107-112. 10.1161/01.STR.0000149627.30763.f9.
80. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology 1981, 10(2):122-126. 10.1002/ana.410100203.
81. Whitwell J.L., Tosakulwong N., Weigand S.D., Senjem M.L., Lowe V.J., Gunter J.L., et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. NeuroImage: Clinical 2013, 2:249-257.
82. Winocur G., Wojtowicz J.M., Sekeres M., Snyder J.S., Wang S. Inhibition of neurogenesis interferes with hippocampus-dependent memory function. Hippocampus 2006, 16(3):296-304. 10.1002/hipo.20163.
83. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250(4978):279-282.
84. Zelinski E.L., Hong N.S., Tyndall A.V., Halsall B., McDonald R.J. Prefrontal cortical contributions during discriminative fear conditioning, extinction, and spontaneous recovery in rats. Experimental Brain Research 2010, 203(2):285-297. 10.1007/s00221-010-2228-0.